Loading clinical trials...

Vitamin D Plus Fluticasone Propionate | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Vitamin D Plus Fluticasone Propionate

The Addition of Vitamin D to Fluticasone Propionate in the Management of Seasonal Allergic Rhinitis

NCT01103934•University of Chicago

Summary

The objectives of this study would be to see if the addition of vitamin D to fluticasone propionate provides greater symptomatic relief in patients with seasonal allergic rhinitis compared to fluticasone propionate treatment alone.

Eligibility

Age

18 - 45 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Males and females between 18 and 45 years of age.
•2. History of tree, grass and/or ragweed allergic rhinitis.
•3. Positive skin test to tree, grass and/or ragweed antigen.
•4. Positive response to screening nasal challenge.

Exclusion Criteria

•1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
•2. Pregnant or lactating women.
•3. Upper respiratory infection within 14 days of study start.

Locations (1)

The University of Chicago

Chicago, Illinois, United States

Key Dates

Start Date

June 1, 2010

Primary Completion Date

July 1, 2011

Completion Date

July 1, 2011

Last Updated

October 9, 2014

Enrollment

ACTUAL participants

Conditions

Seasonal Allergic Rhinitis

Interventions

Vitamin D3

DRUG

Placebo

DRUG

Fluticasone Propionate

DRUG

A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis

NCT06837233

Seasonal Allergic Rhinitis

View study

COMPLETEDPHASE1

A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients

NCT03570957

Seasonal Allergic Rhinitis

View study

COMPLETEDPHASE3

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 9, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Vitamin D Plus Fluticasone Propionate

Inclusion Criteria

Exclusion Criteria

A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis

A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)

To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray

Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.